kk kkk

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02326361-2A1272227?access_token=83ff96335c2d45a094df02a206a39ff4

yes. It is better for the patient if the gilead chooses starpharmar. yes. It is better for the patient if the gilead chooses starpharmar.

Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking up to two hours and requiring daily administration for either 5 or 10 days.In contrast, Starpharma’s DEP® remdesivir is a highly water-soluble nanoparticle formulation of remdesivir with controlled release properties, which would potentially allow for less frequent dosing and use in a non-hospital setting, such as aged-care. Current formulations of remdesivir are required to be administered intravenously due to the drug’s low solubility, with each infusion taking up to two hours and requiring daily administration for either 5 or 10 days.In contrast, Starpharma’s DEP® remdesivir is a highly water-soluble nanoparticle formulation of remdesivir with controlled release properties, which would potentially allow for less frequent dosing and use in a non-hospital setting, such as aged-care.

This is a good thing. Have you ever had a flu shot? Subcutaneous injections are simpler than intravenous injections. The nurse doesn't have to look for blood vessels. This is a good thing. Have you ever had a flu shot? Subcutaneous injections are simpler than intravenous injections. The nurse doesn't have to look for blood vessels.

Company says the benefit of DEP remdesivir’s enhanced aqueous solubility is that it would enable subcutaneous injection rather than intravenous infusionhttps://news.bloomberglaw.com/health-law-and-business/starpharma-creates-water-soluble-formulation-of-remdesivir

!!!!!!!Oncology company PharmAust (PAA) has announced recent testing of two drugs has shown they both succesfully suppressed the infectivity of COVID-19 virus particles by up to 95 per cent.